Global Nasal Vaccines Market

Nasal Vaccines Comprehensive Study by Type (Flu Vaccines, COVID-19 Vaccines, Other Vaccines), Application (Adult, Children), End User (Hospital, Clinic, Public Health Agency, Other) Players and Region - Global Market Outlook to 2030

Nasal Vaccines Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Nasal Vaccines
Nasal vaccines are the administration of mucosal vaccines through nasal route using a nasal sprayer or intra-nasal drop. Mucosal infections are caused by several groups of bacteria and viruses. Nasal vaccines, due to their non-invasiveness, easy access and better immunization are emerging as viable administration alternate to oral or intramuscular administrations. Nasal vaccines may confer protection to the mucosa of lungs, genital tract and intestines.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global nasal vaccine market is fragmented due to the presence of several manufacturers at the global and regional levels. The level of competition among the companies in the nasal drug delivery technology market is intense and manufacturers focus on developing customized products for the customers. The companies are seeking ways to reduce cost, improve product quality, and production efficiency. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Nasal Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sanofi (France), AstraZeneca (United Kingdom), Abbott (United States), GlaxoSmithKline (United Kingdom), Serum Institute of India (India), Bharat Biotech (India), Antares Pharma (Unites States), INJEX Pharma GmbH (Germany), BioDiem (Australia), PharmaJet (United States) and Crossject (France) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Nasal Vaccines market by Type (Flu Vaccines, COVID-19 Vaccines and Other Vaccines), Application (Adult and Children) and Region.



On the basis of geography, the market of Nasal Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Hospital will boost the Nasal Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Adoption Of Self-Administration Practices

Market Growth Drivers:
Increasing Prevalence Of Respiratory Diseases and Preference For Nasal Vaccines

Challenges:
Lack of Consumers’ Awareness

Restraints:
Patent Expiry of Several Vaccines

Opportunities:
Growing Use Of Over-The-Counter (OTC) Nasal Vaccines and Demand For Versatile And Reliable Vaccines Methods

In September 2022, China had approved an inhaled Covid vaccine, administered in the form or a spray. Scientists say that nasal vaccines may offer added immunity in the lining of the nose and upper airways, where Covid typically enters the body.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Nasal Vaccine Providers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End User Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Flu Vaccines
  • COVID-19 Vaccines
  • Other Vaccines
By Application
  • Adult
  • Children
By End User
  • Hospital
  • Clinic
  • Public Health Agency
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence Of Respiratory Diseases
      • 3.2.2. Preference For Nasal Vaccines
    • 3.3. Market Challenges
      • 3.3.1. Lack of Consumers’ Awareness
    • 3.4. Market Trends
      • 3.4.1. Growing Adoption Of Self-Administration Practices
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nasal Vaccines, by Type, Application, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Nasal Vaccines (Value)
      • 5.2.1. Global Nasal Vaccines by: Type (Value)
        • 5.2.1.1. Flu Vaccines
        • 5.2.1.2. COVID-19 Vaccines
        • 5.2.1.3. Other Vaccines
      • 5.2.2. Global Nasal Vaccines by: Application (Value)
        • 5.2.2.1. Adult
        • 5.2.2.2. Children
      • 5.2.3. Global Nasal Vaccines by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinic
        • 5.2.3.3. Public Health Agency
        • 5.2.3.4. Other
      • 5.2.4. Global Nasal Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Nasal Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Serum Institute of India (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bharat Biotech (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Antares Pharma (Unites States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. INJEX Pharma GmbH (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BioDiem (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. PharmaJet (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Crossject (France)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Nasal Vaccines Sale, by Type, Application, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Nasal Vaccines (Value)
      • 7.2.1. Global Nasal Vaccines by: Type (Value)
        • 7.2.1.1. Flu Vaccines
        • 7.2.1.2. COVID-19 Vaccines
        • 7.2.1.3. Other Vaccines
      • 7.2.2. Global Nasal Vaccines by: Application (Value)
        • 7.2.2.1. Adult
        • 7.2.2.2. Children
      • 7.2.3. Global Nasal Vaccines by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinic
        • 7.2.3.3. Public Health Agency
        • 7.2.3.4. Other
      • 7.2.4. Global Nasal Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nasal Vaccines: by Type(USD Million)
  • Table 2. Nasal Vaccines Flu Vaccines , by Region USD Million (2018-2023)
  • Table 3. Nasal Vaccines COVID-19 Vaccines , by Region USD Million (2018-2023)
  • Table 4. Nasal Vaccines Other Vaccines , by Region USD Million (2018-2023)
  • Table 5. Nasal Vaccines: by Application(USD Million)
  • Table 6. Nasal Vaccines Adult , by Region USD Million (2018-2023)
  • Table 7. Nasal Vaccines Children , by Region USD Million (2018-2023)
  • Table 8. Nasal Vaccines: by End User(USD Million)
  • Table 9. Nasal Vaccines Hospital , by Region USD Million (2018-2023)
  • Table 10. Nasal Vaccines Clinic , by Region USD Million (2018-2023)
  • Table 11. Nasal Vaccines Public Health Agency , by Region USD Million (2018-2023)
  • Table 12. Nasal Vaccines Other , by Region USD Million (2018-2023)
  • Table 13. South America Nasal Vaccines, by Country USD Million (2018-2023)
  • Table 14. South America Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 15. South America Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 16. South America Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 17. Brazil Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 18. Brazil Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 19. Brazil Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 20. Argentina Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 21. Argentina Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 22. Argentina Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 23. Rest of South America Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 24. Rest of South America Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 25. Rest of South America Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 26. Asia Pacific Nasal Vaccines, by Country USD Million (2018-2023)
  • Table 27. Asia Pacific Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 28. Asia Pacific Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 29. Asia Pacific Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 30. China Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 31. China Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 32. China Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 33. Japan Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 34. Japan Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 35. Japan Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 36. India Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 37. India Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 38. India Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 39. South Korea Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 40. South Korea Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 41. South Korea Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 42. Taiwan Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 43. Taiwan Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 44. Taiwan Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 45. Australia Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 46. Australia Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 47. Australia Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 51. Europe Nasal Vaccines, by Country USD Million (2018-2023)
  • Table 52. Europe Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 53. Europe Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 54. Europe Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 55. Germany Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 56. Germany Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 57. Germany Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 58. France Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 59. France Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 60. France Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 61. Italy Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 62. Italy Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 63. Italy Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 64. United Kingdom Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 65. United Kingdom Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 66. United Kingdom Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 67. Netherlands Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 68. Netherlands Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 69. Netherlands Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 70. Rest of Europe Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 71. Rest of Europe Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 72. Rest of Europe Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 73. MEA Nasal Vaccines, by Country USD Million (2018-2023)
  • Table 74. MEA Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 75. MEA Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 76. MEA Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 77. Middle East Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 78. Middle East Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 79. Middle East Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 80. Africa Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 81. Africa Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 82. Africa Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 83. North America Nasal Vaccines, by Country USD Million (2018-2023)
  • Table 84. North America Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 85. North America Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 86. North America Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 87. United States Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 88. United States Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 89. United States Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 90. Canada Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 91. Canada Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 92. Canada Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 93. Mexico Nasal Vaccines, by Type USD Million (2018-2023)
  • Table 94. Mexico Nasal Vaccines, by Application USD Million (2018-2023)
  • Table 95. Mexico Nasal Vaccines, by End User USD Million (2018-2023)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Nasal Vaccines: by Type(USD Million)
  • Table 108. Nasal Vaccines Flu Vaccines , by Region USD Million (2025-2030)
  • Table 109. Nasal Vaccines COVID-19 Vaccines , by Region USD Million (2025-2030)
  • Table 110. Nasal Vaccines Other Vaccines , by Region USD Million (2025-2030)
  • Table 111. Nasal Vaccines: by Application(USD Million)
  • Table 112. Nasal Vaccines Adult , by Region USD Million (2025-2030)
  • Table 113. Nasal Vaccines Children , by Region USD Million (2025-2030)
  • Table 114. Nasal Vaccines: by End User(USD Million)
  • Table 115. Nasal Vaccines Hospital , by Region USD Million (2025-2030)
  • Table 116. Nasal Vaccines Clinic , by Region USD Million (2025-2030)
  • Table 117. Nasal Vaccines Public Health Agency , by Region USD Million (2025-2030)
  • Table 118. Nasal Vaccines Other , by Region USD Million (2025-2030)
  • Table 119. South America Nasal Vaccines, by Country USD Million (2025-2030)
  • Table 120. South America Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 121. South America Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 122. South America Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 123. Brazil Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 124. Brazil Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 125. Brazil Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 126. Argentina Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 127. Argentina Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 128. Argentina Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 129. Rest of South America Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 130. Rest of South America Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 131. Rest of South America Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 132. Asia Pacific Nasal Vaccines, by Country USD Million (2025-2030)
  • Table 133. Asia Pacific Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 134. Asia Pacific Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 135. Asia Pacific Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 136. China Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 137. China Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 138. China Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 139. Japan Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 140. Japan Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 141. Japan Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 142. India Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 143. India Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 144. India Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 145. South Korea Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 146. South Korea Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 147. South Korea Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 148. Taiwan Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 149. Taiwan Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 150. Taiwan Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 151. Australia Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 152. Australia Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 153. Australia Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 154. Rest of Asia-Pacific Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 157. Europe Nasal Vaccines, by Country USD Million (2025-2030)
  • Table 158. Europe Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 159. Europe Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 160. Europe Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 161. Germany Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 162. Germany Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 163. Germany Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 164. France Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 165. France Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 166. France Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 167. Italy Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 168. Italy Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 169. Italy Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 170. United Kingdom Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 171. United Kingdom Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 172. United Kingdom Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 173. Netherlands Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 174. Netherlands Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 175. Netherlands Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 176. Rest of Europe Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 177. Rest of Europe Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 178. Rest of Europe Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 179. MEA Nasal Vaccines, by Country USD Million (2025-2030)
  • Table 180. MEA Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 181. MEA Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 182. MEA Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 183. Middle East Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 184. Middle East Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 185. Middle East Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 186. Africa Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 187. Africa Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 188. Africa Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 189. North America Nasal Vaccines, by Country USD Million (2025-2030)
  • Table 190. North America Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 191. North America Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 192. North America Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 193. United States Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 194. United States Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 195. United States Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 196. Canada Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 197. Canada Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 198. Canada Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 199. Mexico Nasal Vaccines, by Type USD Million (2025-2030)
  • Table 200. Mexico Nasal Vaccines, by Application USD Million (2025-2030)
  • Table 201. Mexico Nasal Vaccines, by End User USD Million (2025-2030)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nasal Vaccines: by Type USD Million (2018-2023)
  • Figure 5. Global Nasal Vaccines: by Application USD Million (2018-2023)
  • Figure 6. Global Nasal Vaccines: by End User USD Million (2018-2023)
  • Figure 7. South America Nasal Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Nasal Vaccines Share (%), by Country
  • Figure 9. Europe Nasal Vaccines Share (%), by Country
  • Figure 10. MEA Nasal Vaccines Share (%), by Country
  • Figure 11. North America Nasal Vaccines Share (%), by Country
  • Figure 12. Global Nasal Vaccines share by Players 2023 (%)
  • Figure 13. Global Nasal Vaccines share by Players (Top 3) 2023(%)
  • Figure 14. Global Nasal Vaccines share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 17. Sanofi (France) Revenue: by Geography 2023
  • Figure 18. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 20. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 21. Abbott (United States) Revenue: by Geography 2023
  • Figure 22. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 24. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 25. Serum Institute of India (India) Revenue: by Geography 2023
  • Figure 26. Bharat Biotech (India) Revenue, Net Income and Gross profit
  • Figure 27. Bharat Biotech (India) Revenue: by Geography 2023
  • Figure 28. Antares Pharma (Unites States) Revenue, Net Income and Gross profit
  • Figure 29. Antares Pharma (Unites States) Revenue: by Geography 2023
  • Figure 30. INJEX Pharma GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 31. INJEX Pharma GmbH (Germany) Revenue: by Geography 2023
  • Figure 32. BioDiem (Australia) Revenue, Net Income and Gross profit
  • Figure 33. BioDiem (Australia) Revenue: by Geography 2023
  • Figure 34. PharmaJet (United States) Revenue, Net Income and Gross profit
  • Figure 35. PharmaJet (United States) Revenue: by Geography 2023
  • Figure 36. Crossject (France) Revenue, Net Income and Gross profit
  • Figure 37. Crossject (France) Revenue: by Geography 2023
  • Figure 38. Global Nasal Vaccines: by Type USD Million (2025-2030)
  • Figure 39. Global Nasal Vaccines: by Application USD Million (2025-2030)
  • Figure 40. Global Nasal Vaccines: by End User USD Million (2025-2030)
  • Figure 41. South America Nasal Vaccines Share (%), by Country
  • Figure 42. Asia Pacific Nasal Vaccines Share (%), by Country
  • Figure 43. Europe Nasal Vaccines Share (%), by Country
  • Figure 44. MEA Nasal Vaccines Share (%), by Country
  • Figure 45. North America Nasal Vaccines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sanofi (France)
  • AstraZeneca (United Kingdom)
  • Abbott (United States)
  • GlaxoSmithKline (United Kingdom)
  • Serum Institute of India (India)
  • Bharat Biotech (India)
  • Antares Pharma (Unites States)
  • INJEX Pharma GmbH (Germany)
  • BioDiem (Australia)
  • PharmaJet (United States)
  • Crossject (France)
Select User Access Type

Key Highlights of Report


Apr 2024 242 Pages 70 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Nasal Vaccines Market Quantitative research analysis
Global Nasal Vaccines Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sanofi (France), AstraZeneca (United Kingdom), Abbott (United States), GlaxoSmithKline (United Kingdom), Serum Institute of India (India), Bharat Biotech (India), Antares Pharma (Unites States), INJEX Pharma GmbH (Germany), BioDiem (Australia), PharmaJet (United States) and Crossject (France) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Adoption Of Self-Administration Practices" is seen as one of major influencing trends for Nasal Vaccines Market during projected period 2023-2030.
The Nasal Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Nasal Vaccines Market Report?

Have a Query? Click Here

Other Related Reports

High-Throughput Screening (HTS) Comprehensive Study by Type (Instruments, Consumables, Software, Service), Application (Drug Discovery, Biochemical Screening, Research, Others), Technology (Cell-Base...
$ 3750
Digital Assistant in Healthcare Comprehensive Study by Type (Rule-Based, Conversational Based), Application (Patient Tracking, Medical Reference, Diagnostic Guides, Drug Dosage, Medical Calculators, ...
$ 3750
Surgical Navigation Systems and Software Comprehensive Study by Application (Orthopedic, ENT, Neurosurgery dental, Cardiac, Others), Technology (Optical, Electromagnetic (EM), Hybrid), Navigation Sys...
$ 3750
Interventional Radiology Imaging Comprehensive Study by Type (MRI System, Ultrasound Imaging System, CT Scanner, Angiography System), Application (Cardiology, Oncology, Urology, Nephrology), Procedur...
$ 3450
Medical Network Solution Comprehensive Study by Type (Software, Services), Delivery Mode (On-premise Delivery Mode, Cloud-based Delivery Mode), End-user (Payer, Private, Public Health Insurers) Playe...
$ 3500
Soft Skeletal Implants Comprehensive Study by Type (Tissue-engineered/Natural Constructs (Skin, Bone, Other Body Tissues), Artificial Constricts /Synthetic Products (Metal, Plastic, Ceramic, Other)),...
$ 3650